Zonisamide for Weight Loss in Obese Adults: A Randomized Controlled Trial

JAMA

Volumn 289, Issue 14, 2003, Pages 1820-1825

  Gadde, Kishore M ^a   Franciscy, Deborah M ^a   Wagner II, H Ryan ^a   Krishnan, K Ranga R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLACEBO; ZONISAMIDE; ANTICONVULSIVE AGENT; ANTIOBESITY AGENT; ISOXAZOLE DERIVATIVE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; VERTIGO; WEIGHT REDUCTION; BODY MASS; CALORIC RESTRICTION; DIET THERAPY; LIFESTYLE; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; ANTICONVULSANTS; BODY MASS INDEX; CALORIC RESTRICTION; COMBINED MODALITY THERAPY; DIET, REDUCING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; LIFE STYLE; MALE; OBESITY; PATIENT EDUCATION; RISK REDUCTION BEHAVIOR; SINGLE-BLIND METHOD; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0038516857     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.14.1820     Document Type: Article

References (24)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
2. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
3. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1529.
4. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-1105.
5. Blackburn GL. Benefits of weight loss in the treatment of obesity. Am J Clin Nutr. 1999;69:347-349.
6. Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? JAMA. 1999;282:1576-1578.
7. National Heart, Lung, and Blood Institute, National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md: National Institutes of Health; September 1998. Publication 98-4083.
8. Oommen KJ, Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol. 1999;22:192-200.
9. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22:193-205.
10. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34:187-197.
11. Kolotkin RL, Head S, Hamilton M, Tse CJ. Assessing impact of weight on quality of life. Obes Res. 1995;3:49-56.
12. Jensen LB, Quaade F, Sorensen OH. Bone loss accompanying voluntary weight loss in obese humans. J Bone Miner Res. 1994;9:459-463.
13. Leppik IE. Zonisamide. Epilepsia. 1999;40:S23-S29.
14. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs. 1998;56:1093-1124.
15. 2+ dependent dopamine release. Epilepsy Res. 1992;13:113-119.
16. Kaneko S, Okada M, Hirano T, Kondo T, Otani K, Fukushima Y. Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread. Jpn J Psychiatry Neurol. 1993;47:371-373.
17. Hashiguti H, Nakahara D, Maruyama W, Naoi M, Ikeda T. Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Transm Gen Sect. 1993;93:213-223.
18. Drago J, Gerfen CR, Lachowicz JE, et al. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc Natl Acad Sci U S A. 1994;91:12564-12568.
19. Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists and feeding behavior. Obes Res. 1995;3:515S-523S.
20. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354-357.
21. Dahl H, Norskov K, Peitersen E, Hilden J. Zinc therapy of acetazolamide-induced side effects. Acta Ophthalmol. 1984;62:739-745.
22. Miller LG, Miller SM. Altered taste secondary to acetazolamide therapy. J Fam Pract. 1990;31:199-200.
23. McMurdo ME, Hutchison GL, Lindsay G. Taste disturbance with acetazolamide. Lancet. 1990;336:1190-1191.
24. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 1999;69:584-596.